Cardiovascular safety of triptans in the acute treatment of migraine

Abstract

The article highlights the issues of safety when using triptans in the treatment of migraine and the risks of cardiovascular complications. Results of a large prospective population study are provided demonstrating that triptans in patients with migraine are not associated with a significantly increased risk of cardiovascular events.

Keywords

• мигрень
• антимигренозные средства
• триптаны
• кардиоваскулярные события
• элетриптан
• migraine
• antimigraine agents
• triptans
• cardiovascular events
• eletriptanum